1, Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC，Doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15.
2, Amivantamab: First Approval， Doi: 10.1007/s40265-021-01561-7.
3, Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). DOI: 10.1200/JCO.2020.38.15_suppl.9512
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC, PMID: 32414908
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis, PMID: 32747419
Development of [ 89 Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer, PMID: 32770372
Antibodies to watch in 2021, PMID: 33459118
Amivantamab-vmjw, PMID: 34219152
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins, PMID: 32979839
Amivantamab: First Approval, PMID: 34292533
Amivantamab, PMID: 34165943
Amivantamab OK'd for EGFR-Mutant NSCLC, PMID: 34083225
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET, PMID: 33839159
Amivantamab Is Active in Platinum-Resistant EGFR ex20-mutant NSCLC, PMID: 34389637
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells, PMID: 27786612
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions, PMID: 34381206
Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation, PMID: 34339261
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, PMID: 34339292
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations, PMID: 34285620
Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions, PMID: 34284994
Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance, PMID: 28830985
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion., PMID:40515576
Prophylaxis We Should Not SKIPP: Reducing Amivantamab-Related Infusion-Related Reactions With Dexamethasone., PMID:40484483
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan., PMID:40481943
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab., PMID:40450572
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773
Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer., PMID:40446181
Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib., PMID:40439479
Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort study., PMID:40408939
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration., PMID:40397846
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis., PMID:40396122
Advancing Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion-Mutated Non-small Cell Lung Cancer (NSCLC) Management Through Molecular Diagnostics and Targeted Therapies., PMID:40390745
Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations., PMID:40385479
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study., PMID:40383434
[Amivantamab with lazertinib - stage IV non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation]., PMID:40379500
Lazertinib: a novel EGFR-TKI therapy for non-small cell lung cancer., PMID:40372786
Further-Line Treatment With Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC: New Answers to Old Questions?, PMID:40348479
Efficacy and safety outcomes of emerging EGFR‑TKIs for patients with non‑small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta‑analysis., PMID:40337604
Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations., PMID:40328075
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer., PMID:40326044
Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations., PMID:40324662
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset., PMID:40300278
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment., PMID:40277763
Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA., PMID:40270251
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study., PMID:40262227
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer., PMID:40248718
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer., PMID:40220717
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan., PMID:40214878
FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone., PMID:40213223
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer., PMID:40192238
Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer., PMID:40171939
[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]., PMID:40155080
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab., PMID:40154460
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials., PMID:40154402
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials., PMID:40154322
Recent advances in therapeutic strategies for non-small cell lung cancer., PMID:40140911
Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions., PMID:40136378
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting., PMID:40118657
Papillon trial, a major advance in the management of patients with metastatic, mutated-EGFR exon 20 insertion non-small-cell lung cancer., PMID:40081391
A new era for EGFR exon20 targeting in non-small cell lung cancer., PMID:40081390
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis., PMID:40081325
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib., PMID:40075694
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system., PMID:40001304
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)., PMID:39986216
Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer., PMID:39965618
Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis., PMID:39951884
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer., PMID:39935000
For research use only. Not for human or drug use.
